Specialized in TCM new drug development and healthy food development and production, Microbio(4128) set OTC price with 12 NTD per share on June 9th, and taking effectively till May 29 allocate 840000 shares for public offer, the OTC public hearing will take place on Regent Hotel on June 8th 2:00PM

Taking advantage from national wide distribution success and healthy food sales continuous growth, sales of April reached to 2500 million NTD which is 79.32% higher than same moth last year, with accumulation of recent 4 months, sales revenue increased 108.82%. Microbio business operation turned from minus to plus last year, with actual revenue income of 199 million NTD, 260% increase in sales, gross income 190 million NTD, EPS 0.03, the board decided not to allocate any interests, regular meeting will be held on May the 29th.

Microbio is established in year 2000, besides of TCM new drug discovery, there are there three major categories: symbiotic fermentation series, Lee Herbs product series, ODM series with sales of 33% evenly.

For fermented extract series, it includes Young with two health food certification approved by DOH; health food "Lee Herbs" with over 38 products on the market; and ODM series includes Youth series, Rhoto Japan's purified bean extract and Fromme skin care series, all these through diversity in order to minimize the operational risks.

Establishment of over 1000 spot for distribution

Microbio noted, starting from last year of collaboration with TCM pharmacy store, there are over 1000 spots established under "Lee Herbs" and expected to increase up to 1500 sales points for this year, and also 200 Fromme Vigor Health spots. Microbio is aggressively expanding market share, and push outward to oversea such as Japan, Singapore, Middle East, and other foreign market as well as for China distribution deployment with Shanghai plant estalishement, and another 3000 health stores "Health Column" expected. All these will bring about new momentum for company's sales operation.

The strategy that Microbio considered is periodic operation in health food market, which will bring in cash flow to help out new drug development, a simultaneous running of both new drug and channel distribution to ensure R&D capability. To be noted, MS-20 will file Phase II IND submission under FDA, which is a DOH approved cancer adjuvant for Phase III HIND study in Taiwan.